Prognostic Factors in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Retrospective Comparison with Previously Known Prognostic Models

Publisher： Karger

E-ISSN： 1423-0232|80|3-4|167-174

ISSN： 0030-2414

Source： Oncology, Vol.80, Iss.3-4, 2011-06, pp. : 167-174

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prognostic Factors in Patients with Hepatocellular Carcinoma Refractory or Intolerant to Sorafenib

By  

Oncology, Vol. 88, Iss. 4, 2014-12 ,pp. : 241-246

Karger

Access to resources Recommend Favorite

A Single-Institute Experience with Sorafenib in Untreated and Previously Treated Patients with Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 78, Iss. 3-4, 2010-04 ,pp. : 210-212

Karger

Access to resources Recommend Favorite

Evaluation of the mRECIST and α-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib

By  

Oncology, Vol. 83, Iss. 4, 2012-08 ,pp. : 192-200

Karger

Access to resources Recommend Favorite

Efficacy, Safety, and Survival Factors for Sorafenib Treatment in Japanese Patients with Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 84, Iss. 2, 2012-11 ,pp. : 108-114

Karger

Access to resources Recommend Favorite

Potential Prognostic Benefits of Radiotherapy as an Initial Treatment for Patients with Unresectable Advanced Hepatocellular Carcinoma with Invasion to Intrahepatic Large Vessels

By  

Oncology, Vol. 73, Iss. 1-2, 2008-03 ,pp. : 90-97

Karger

Access to resources Recommend Favorite